Stay updated on IBI310 Combo vs Sorafenib in HCC Clinical Trial
Sign up to get notified when there's something new on the IBI310 Combo vs Sorafenib in HCC Clinical Trial page.

Latest updates to the IBI310 Combo vs Sorafenib in HCC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.3%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe web page has been updated to reflect a new version, changing from v2.14.4 to v2.15.0.SummaryDifference0.9%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.3%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check88 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference5%
- Check95 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.3%
Stay in the know with updates to IBI310 Combo vs Sorafenib in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IBI310 Combo vs Sorafenib in HCC Clinical Trial page.